SG 2918
Alternative Names: SG-2918Latest Information Update: 15 Dec 2023
At a glance
- Originator Hangzhou Sumgen Biotech
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 29 Nov 2023 Phase-I clinical trials in Cancer (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT06167486)
- 10 Jun 2022 Preclinical trials in Cancer in China (Parenteral) before June 2022 (Sumgen Biotech pipeline, June 2022)
- 10 Jun 2022 Sumgen Biotech intends to submit IND application in Cancer in 2022 (Sumgen Biotech pipeline, June 2022)